AI Article Synopsis
- A study analyzed adverse events in ovarian cancer patients switching from olaparib capsules to tablets, using a retrospective design over a four-year period.
- Of 48 patients, 45.8% experienced adverse events during the first 90 days on capsules, compared to 35.4% on tablets, showing a 10.4% decrease in events after the switch.
- The findings suggest that switching to olaparib tablets is manageable and does not increase toxicity, indicating good tolerability for patients.
Article Abstract
Describe rates of prespecified adverse events in patients who switched from olaparib capsules to tablets. Retrospective, observational cohort analysis using self-controlled, pre-post design. Data on patients with ovarian cancer who switched from olaparib capsules to tablets between January 2015 and February 2019 were obtained from a US claims database. Among all patients (n = 48), proportion with any prespecified adverse event was 45.8% (95% confidence interval: 31.4-60.8) during initial 90 days' capsule use and 35.4% (22.2-50.5) during initial 90 days' tablets use; difference -10.4% (-28.8-9.0). Switching from olaparib capsules to tablets was manageable with no evidence of increased toxicity. This real-world study supports the manageable tolerability of olaparib in women with ovarian cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2020-0142 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intestine-Decipher Engineered Capsules Protect Against Sepsis-induced Intestinal Injury via Broad-spectrum Anti-inflammation and Parthanatos Inhibition.
Adv Sci (Weinh)
January 2025
School of Inspection, Ningxia Medical University, Yinchuan, Ningxia, 750004, China.
Sepsis is a severe systemic inflammatory syndrome characterized by a dysregulated immune response to infection, often leading to high mortality rates. The intestine, owing to its distinct structure and physiological environment, plays a pivotal role in the pathophysiology of sepsis. It functions as the "central organ" or "engine" in the progression of sepsis, with intestinal injury exacerbating the condition.
View Article and Find Full Text PDFComparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial Ovarian Cancer: A Nationwide Propensity Score Matched Cohort Study.
Target Oncol
March 2024
Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, 03772, Republic of Korea.
Background: Despite improvement in progression-free survival (PFS) with poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) as maintenance treatment for patients with epithelial ovarian cancer (EOC), a comparative analysis of clinical events of interest (CEIs) of different PARPi is scarce.
Objective: This study aimed to compare the safety of different PARPi in patients with EOC.
Patients And Methods: Through analyzing the Korean National Health Insurance Service from January 2009 to January 2022, this study involved BRCA-mutated, platinum-sensitive patients with EOC treated with olaparib (tablet), niraparib, and olaparib (capsule) as first-line or second-line maintenance treatment.
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Eur J Cancer
November 2023
Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands.
Background: Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of olaparib, a CYP3A-substrate, has the potential to reduce PK variability and financial burden. The aim of this study was to investigate equivalence of a boosted, reduced dose of olaparib compared to the non-boosted standard dose.
View Article and Find Full Text PDFMaintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Gynecol Oncol
May 2023
The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
Article Synopsis
- The ORZORA trial tested the effectiveness and safety of olaparib as a maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer who have BRCA mutations or non-BRCA homologous recombination repair mutations after prior chemotherapy.
- The study involved 177 patients who received olaparib, with a median follow-up showing progression-free survival rates varying between 16.4 and 19.3 months depending on mutation type.
- Results indicated that most patients with BRCA mutations either improved or maintained their quality of life, and the safety profile of olaparib was consistent with expectations, reinforcing its use for these patients.
Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis.
Cancer Chemother Pharmacol
April 2023
European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.
Purpose: For patients with severe renal impairment (CrCl ≤ 30 ml/min) or end-stage renal disease (ESRD), olaparib intake is not recommended as the pharmacokinetics and safety of olaparib have not been evaluated in this patient group. Therefore, this valuable patient group is generally excluded from poly(ADP-ribose) polymerase inhibitor (PARPi) therapy. Here we report the pharmacokinetics (PK), efficacy, safety and tolerability of olaparib capsules 200 mg BID in a patient with recurrent epithelial ovarian cancer (EOC) and ESRD requiring hemodialysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!